Similar articles

• Telithromycin and acute liver failure.

  Graham DJ. Graham DJ. N Engl J Med. 2006 Nov 23;355(21):2260-1. doi: 10.1056/NEJMc066372. N Engl J Med. 2006. PMID: 17124030 No abstract available.
• The FDA and the case of Ketek.

  Ross DB. Ross DB. N Engl J Med. 2007 Apr 19;356(16):1601-4. doi: 10.1056/NEJMp078032. N Engl J Med. 2007. PMID: 17442902 No abstract available.
• Fraud, errors taint a key study of widely used Sanofi drug; despite some faked results, FDA approves antibiotic; one doctor's cocaine use; company defends safety.

  Mathews AW. Mathews AW. Wall St J (East Ed). 2006 May 1:A1, A12. Wall St J (East Ed). 2006. PMID: 16838449 No abstract available.
• Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.

  Echols RM. Echols RM. Ann N Y Acad Sci. 2011 Dec;1241:153-61. doi: 10.1111/j.1749-6632.2011.06300.x. Ann N Y Acad Sci. 2011. PMID: 22191531 Review.
• Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.

  Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM. Clay KD, et al. Ann Intern Med. 2006 Mar 21;144(6):415-20. doi: 10.7326/0003-4819-144-6-200503210-00121. Epub 2006 Feb 15. Ann Intern Med. 2006. PMID: 16481451 Review.